Gilgamesh Pharma Closes Oversubscribed $60 Million Series A to Develop Next Generation Neuropsychiatric Therapies
Prnewswire·2026-03-24 16:01
Gilgamesh Pharma Closes Oversubscribed $60 Million Series A to Develop Next Generation Neuropsychiatric Therapies Accessibility StatementSkip NavigationNEW YORK, March 24, 2026 /PRNewswire/ -- Gilgamesh Pharma, a clinical-stage neuroscience company developing breakthrough therapies for psychiatric and neurological disorders, today announced the successful closing of a $60 million Series A financing. The strong investor demand reflects the high quality of the company's clinical and preclinical pipeline.This ...